



6 - 28 - 05

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/616,692
Applicant : Jodi Nelson
Filed : July 9, 2003
Title : COMPOSITIONS AND METHODS FOR THE
TREATMENT OF PARKINSON'S DISEASE
AND TARDIVE DYSKINESIAS

Confirmation No. 1639

TC/A.U. : 1614

Examiner : Unassigned

Docket No. : 47-00B

Customer No.: 23713

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as Express Mail in an envelope addressed to: Mail Stop Amendment,
Hon. Commissioner for Patents, PO Box 1450,
Alexandria VA 22313-1450 EV 663226231 US

June 27, 2005 *Andrea Ryder*
Date Andrea Ryder

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner for Patents
Washington, D.C. 20231

Sir:

This application is a continuation-in-part of USSN 10/192,414, filed July 9, 2002, which is a continuation-in-part of USSN 09/615,639, filed July 13, 2000 (now U.S. Patent No. 6,417,177). In compliance with the duty of disclosure set forth in 37 C.F.R. 1.97, the Examiner is referred to the files of those applications for prior art of record. For the Examiner's convenience, a supplemental list of the references recently made of record in Serial No. 09/615,639 is provided on the enclosed Patent and Trademark Office Form PTO-1449.

It is believed that this submission does not necessitate the payment of any fees; however, if this is incorrect, please charge any requisite fee to Deposit Account 07-1969.

Respectfully submitted,



Ellen P. Winner
Reg. No. 28,547

GREENLEE, WINNER and SULLIVAN, P.C.
5370 Manhattan Circle, Suite 201
Boulder, CO 80303
Phone (303) 499-8080
Fax (303) 499-8089
air: June 27, 2005
Docket 47-00B

Substitute for form 1449/PTO, based on PTO/SB/08A and 08B

Application Number

10/616,692

Filing Date

July 9, 2003

First Named Inventor

Nelson, Jodi

Art Unit

1614

Examiner Name

Unassigned

Attorney Docket Number

47-00B



GWS 6/27/2005

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

U.S. PATENT DOCUMENTS

Examiner Initial*	Cite No. ¹	Document Number (US-)	Publication Date (MM-DD-YYYY)	Name	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear (or entire document unless noted otherwise)

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No. ¹	Foreign Patent Document Number (include WIPO country code)	Publication Date (MM-DD-YYYY)	Name	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear (or entire document unless noted otherwise)	T ²

NON-PATENT LITERATURE DOCUMENTS

Examiner Initial*	Cite No. ¹	REFERENCE	T ²
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
		Ben-Shachar, D. et al. (1993), "Iron, melanin and dopamine interaction: Relevance to Parkinson's disease," Progress in Neuro-Psychopharmacology and Biological Psychiatry, 17(1):139-150.	
		D'Ischia Marco et al. (1997) "Biosynthesis, structure and function of neuromelanin and its relation to Parkinson's disease: a critical update," Pigment Cell Research 10(6):370-376.	
		Garcia Ruiz, P.J., et al. (1992), "Cinnarizine-induced parkinsonism in primates," Clinical neuropharmacology 15(2):152-154 (Abstract)	
		Garcia-Ruiz, P.J., et al. (1992) "Parkinsonism associated with calcium channel blockers: a prospective follow-up study," Clinical Neuropharmacology 15(1):19-26 (Abstract)	
		Geddes, J.F., et al. (1993), "Pathological overlap in cases of parkinsonism associated with neurofibrillary tangles. A study of recent cases of postencephalitic parkinsonism and comparison with progressive supranuclear palsy and Guamanian parkinsonism-dementia complex," Brain, (Pt 1):281-302 (Abstract).	
		Hayase, Y, et al. (1997), "Influenza virus and neurological diseases," Psychiatry Clin. Neurosci. 41(4):181-4 (Abstract).	
		Kuzuhara S., et al. (1989), "Parkinsonism, depression and akathisia induced by flunarizine, a calcium entry blockade-report of 31 cases," Rinsho shinkeigaku (Japan) 29 (6):681-686 (Abstract)	

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional).

²Applicant is to place a check mark here or "x" if English language Translation is attached.

Substitute for form 1449/PTO, based on PTO/SB/08A and 08B

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Application Number	10/616,692
Filing Date	July 9, 2003
First Named Inventor	Nelson, Jodi
Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	47-00B

GWS 6/27/2005

Examiner Initial*	Cite No. ¹	REFERENCE Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Majno, G. et al. (1995), "Apoptosis, Oncosis, and Necrosis, An overview of Cell Death," American J. Pathology 146(1):3-16.	
		Negrotti, A. et al. (1992), "Calcium-entry blockers-induced parkinsonism: possible role of inherited susceptibility," Neurotoxicology 13(1):261-4 (Abstract)	
		Savenko, S.N., et al. (1975), "Histamine metabolism in patients with cerebral circulatory disorders together with hypertension and cerebral atherosclerosis," Zh Nevropatol Psichiatr Im S S Korsakova 75(8):1162-7 (Abstract)	
		Takahashi, A., et al. (1993), "Drug-induced movement disorders," Nippon rinsho (JAPAN) 51(11):2929-34 (Abstract)	
		Tatton, N.A., et al. (Sept. 1998), "A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease," Annals of Neurology 44(3 Suppl 1):S142-148 (Abstract)	
		Tatton, W.G., et al. (Sept., 1998), "Mitochondria in Neurodegenerative Apoptosis: an Opportunity for Therapy?" Annals of Neurology 44(3 Suppl. 1): S134-41 (Abstract)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional).

²Applicant is to place a check mark here or "x" if English language Translation is attached.